CS
XENE icon

Credit Suisse’s Xenon Pharmaceuticals XENE Stock Holding History

Credit Suisse’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$3.67M Buy
85,339
+3,544
+4% +$163K ﹤0.01% 1475
2023
Q4 		$3.77M Buy
81,795
+16,209
+25% +$573K ﹤0.01% 1505
2023
Q3 		$2.24M Sell
65,586
-241
-0.4% -$9.01K ﹤0.01% 1757
2023
Q2 		$2.53M Buy
65,827
+7,757
+13% +$308K ﹤0.01% 1756
2023
Q1 		$2.08M Buy
58,070
+3,281
+6% +$121K ﹤0.01% 1844
2022
Q4 		$2.16M Buy
54,789
+11,136
+26% +$406K ﹤0.01% 1823
2022
Q3 		$1.58M Buy
43,653
+10,469
+32% +$376K ﹤0.01% 2013
2022
Q2 		$1.01M Buy
33,184
+3,034
+10% +$91.8K ﹤0.01% 2372
2022
Q1 		$922K Buy
30,150
+5,246
+21% +$157K ﹤0.01% 2593
2021
Q4 		$777K Buy
24,904
+6,206
+33% +$185K ﹤0.01% 3511
2021
Q3 		$286K Buy
18,698
+81
+0.4% +$1.41K ﹤0.01% 4103
2021
Q2 		$346K Sell
18,617
-5,474
-23% -$101K ﹤0.01% 4043
2021
Q1 		$432K Buy
24,091
+5,613
+30% +$95.1K ﹤0.01% 3857
2020
Q4 		$283K Buy
18,478
+4,793
+35% +$56.1K ﹤0.01% 4002
2020
Q3 		$151K Hold
13,685
– – ﹤0.01% 3888
2020
Q2 		$172K Buy
+13,685
New +$174K ﹤0.01% 3770
2019
Q3 		– Sell
-14,512
Closed -$143K – 4280
2019
Q2 		$143K Buy
+14,512
New +$139K ﹤0.01% 3903

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse's XENE Position: Q1 2024 in Review

Credit Suisse increased its Xenon Pharmaceuticals (XENE) stake by 4.3% in Q1 2024, buying an estimated $163K and bringing the position to 85,339 shares worth $3.67M. The position accounts for ﹤0.01% of the portfolio, ranked #1475.

Credit Suisse first reported a position in XENE in Q2 2019 and has held it in 17 quarters since. The position peaked at $3.77M in Q4 2023. 220 funds tracked by Wall St. Rank hold XENE as of Q1 2024.

  • Credit Suisse held 85,339 shares of Xenon Pharmaceuticals worth $3.67M as of Q1 2024.
  • Credit Suisse bought 3,544 Xenon Pharmaceuticals shares in Q1 2024, an estimated $163K.
  • Xenon Pharmaceuticals made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1475 holding.
  • Credit Suisse first reported a position in Xenon Pharmaceuticals in Q2 2019 and has held it in 17 quarters since.
  • Credit Suisse's Xenon Pharmaceuticals position peaked at $3.77M in Q4 2023.
  • 220 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.